Masimo is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors.

  • Capnography Solutions
  • Partnering with caregivers and patient monitoring companies to provide a complete portfolio of capnography and gas monitoring solutions
  • rainbow® Pulse CO-Oximetry
  • The Masimo rainbow SET™ platform has the unique ability to measure dyshemoglobins and total hemoglobin concentration.
  • CCHD Screening
  • Reliable, Accurate Screening for Critical Congenital Heart Disease (CCHD) with Masimo SET®

News & Media

  • March 6, 2018
  • Las Vegas, Nevada
  • Las Vegas, Nevada – March 6, 2018 – Today at the 2018 HIMSS Annual Conference Masimo (NASDAQ: MASI) announced the release of Replica™, an application for smart phones and tablets that works in conjunc […]
  • February 26, 2018
  • Bangalore, India
  • Masimo (NASDAQ: MASI) announced today that NU Hospitals, a leading nephrology care center in India, has standardized on Masimo technologies across the continuum of care. NU Hospitals have entered int […]
  • February 22, 2018
  • Irvine, California
  • Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Michigan State University evaluated the performance of noninvasive hemodynamic monitoring (NIHM […]
  • January 1, 2010
  • Masimo SET $1 Million Performance Guarantee
  • In keeping with Masimo’s mission to improve patient care, and to help clinicians separate fact from fiction, Masimo is renewing and expanding its performance guarantee. If Masimo SET® is proven not to […]
  • February 23, 2018
  • Patient Safety Movement
  • The Patient Safety Movement Foundation believes reaching ZERO preventable deaths in hospitals by 2020 (0X2020™) is not only the right goal, but an attainable one with the right people, ideas, and tech […]
  • May 1, 2017
  • 2016 Masimo Annual Report
  • 2016 Masimo Annual Report - Through Movement. The first phase of our 10-year plan was to invest in R&D and key functional areas, allowing the company to gain a worldwide presence sufficient to facilit […]

Rad-97, Next Generation SedLine, ISA AX+, and ISA OR+ are not licensed for sale in Canada.
Neonatal NomoLine and ISA products are currently available in the United States only.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.